Medpace (NASDAQ:MEDP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Medpace (NASDAQ:MEDP) from a hold rating to a buy rating in a research report released on Saturday morning.

A number of other equities analysts also recently commented on MEDP. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and upped their target price for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Barclays upped their target price on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a report on Friday. TD Cowen upped their target price on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a report on Friday. Weiss Ratings restated a “buy (b-)” rating on shares of Medpace in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and upped their target price for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $475.90.

Medpace Stock Performance

Shares of MEDP stock opened at $596.48 on Friday. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The stock has a 50 day moving average price of $505.80 and a two-hundred day moving average price of $394.74. The company has a market capitalization of $16.80 billion, a P/E ratio of 41.71, a PEG ratio of 3.58 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the previous year, the company posted $3.01 earnings per share. The business’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts predict that Medpace will post 12.29 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Cornelius P. Mccarthy III sold 1,662 shares of the company’s stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the sale, the director directly owned 10,197 shares of the company’s stock, valued at $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Susan E. Burwig sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total value of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares in the company, valued at approximately $27,600,000. The trade was a 14.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,478 shares of company stock valued at $23,093,073 over the last ninety days. Company insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quent Capital LLC purchased a new stake in shares of Medpace in the third quarter worth $25,000. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group grew its stake in shares of Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after acquiring an additional 71 shares during the last quarter. Whittier Trust Co. grew its stake in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new stake in shares of Medpace in the second quarter worth $36,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.